Literature DB >> 34453643

Liver Cirrhosis, Etiology and Clinical Characteristics Disparities Among Minority Population.

Muhammad Abu Tailakh1,2, Liat Poupko3, Najwan Kayyal4, Ali Alsana4, Asia Estis-Deaton4, Ohad Etzion5,6, Alexander Fich5,6, David Yardni5,6, Naim Abu-Freha7,8.   

Abstract

Liver cirrhosis (LC) is a common disease with varied primary causes and ethnic disparities. Clinical characteristics and outcomes of Arab Bedouin (AB) and Jewish patients with LC were retrospective collected and compared. We included 1048 patients, 95 (9%) Arab Bedouin and 953 (91%) Jewish patients. The incidence of cirrhosis was much lower among AB. Age at diagnosis was 47 ± 18 years among Bedouins compared to 61 ± 13 years (p < 0.001) among Jews. The most frequent causes of cirrhosis among Bedouin patients were fatty liver 21.1%, cryptogenic 20%, hepatitis B 17.9% and autoimmune hepatitis 15.8%, while hepatitis C (39.2%), fatty liver (17.2%) and alcoholic liver disease (14.4%) were most common among Jewish patients. An all-cause mortality of 48.4% was observed in AB patients compared to 66.4% in Jewish patients (p < 0.001). Significant disparities regarding incidence, clinical characteristics and outcomes of cirrhosis among Arab Bedouin compared with Jewish population were found.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Arab Bedouin; Cirrhosis; Complications; Jews; Mortality

Mesh:

Year:  2021        PMID: 34453643     DOI: 10.1007/s10903-021-01263-y

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  8 in total

1.  Inflammatory bowel disease among Bedouin Arabs in southern Israel: urbanization and increasing prevalence rates.

Authors:  Naim Abu Freha; Doron Schwartz; Jaber Elkrinawi; Gil Ben Yakov; Muhammad Abu Tailakh; Daniela Munteanu; Abdelrhman Abu Ganim; Alexander Fich
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-03       Impact factor: 2.566

Review 2.  The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis.

Authors:  Johannes Wiegand; Thomas Berg
Journal:  Dtsch Arztebl Int       Date:  2013-02-08       Impact factor: 5.594

3.  Diabetes among Bedouins in the Negev: the transition from a rare to a highly prevalent condition.

Authors:  Yunis Abou-Rbiah; Shimon Weitzman
Journal:  Isr Med Assoc J       Date:  2002-09       Impact factor: 0.892

4.  Differences in food intake and disparity in obesity rates between adult Jews and Bedouins in southern Israel.

Authors:  Drora Fraser; Natalya Bilenko; Hillel Vardy; Kathleene Abu-Saad; Iris Shai; Heijar Abu-Shareb; Danit R Shahar
Journal:  Ethn Dis       Date:  2008       Impact factor: 1.847

5.  Autoimmune hepatitis in southern Israel: a 15-year multicenter study.

Authors:  Jorge-Shmuel Delgado; Alina Vodonos; Stephen Malnick; Ofra Kriger; Renana Wilkof-Segev; Bertha Delgado; Victor Novack; Alexander Rosenthal; Yoram Menachem; Ehud Melzer; Alexander Fich
Journal:  J Dig Dis       Date:  2013-11       Impact factor: 2.325

6.  Cardiovascular risk factors in the Bedouin population: management and compliance.

Authors:  Oren Tamir; Roni Peleg; Jacob Dreiher; Talab Abu-Hammad; Yunis Abu Rabia; Mohammad Abu Rashid; Alex Eisenberg; David Sibersky; Alex Kazanovich; Elbedour Khalil; Daniel Vardy; Pesach Shvartzman
Journal:  Isr Med Assoc J       Date:  2007-09       Impact factor: 0.892

Review 7.  Burden of Gastrointestinal and Liver Diseases in Middle East and North Africa: Results of Global Burden of Diseases Study from 1990 to 2010.

Authors:  Sadaf Ghajarieh Sepanlou; Fatemeh Malekzadeh; Farnaz Delavari; Mohsen Naghavi; Mohammad Hossein Forouzanfar; Maziar Moradi-Lakeh; Reza Malekzadeh; Hossein Poustchi; Akram Pourshams
Journal:  Middle East J Dig Dis       Date:  2015-10

8.  Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.

Authors:  Astrid Marot; Jean Henrion; Jean-François Knebel; Christophe Moreno; Pierre Deltenre
Journal:  PLoS One       Date:  2017-10-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.